Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
出版年份 2016 全文链接
标题
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF SURGERY
Volume 103, Issue 7, Pages 845-854
出版商
Wiley
发表日期
2016-03-08
DOI
10.1002/bjs.10127
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy
- (2014) Minoru Miyashita et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
- (2014) Yan Mao et al. PLoS One
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer
- (2013) S. Kashiwagi et al. BRITISH JOURNAL OF SURGERY
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2013) Hee Jin Lee et al. Journal of Breast Cancer
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Impact of Tumor-infiltrating Lymphocytes for Survival in Curatively Resected Stage IV Colon Cancer with Isolated Liver or Lung Metastasis
- (2012) Won-Suk Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients
- (2012) Naofumi Oda et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer
- (2012) Hui Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence
- (2011) Petr Kocián et al. HUMAN IMMUNOLOGY
- The mechanisms of cancer immunoescape and development of overcoming strategies
- (2011) Tomonori Yaguchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
- (2010) M. W. L. Teng et al. CANCER RESEARCH
- Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
- (2010) Horlad Hasita et al. CANCER SCIENCE
- Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma
- (2008) Helena Hornychová et al. CANCER INVESTIGATION
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started